One of the cruel ironies of proxy season, the time of the year when most companies tell us how much they paid their top executives, is that it comes when the rest of us are scrambling to file our tax returns.
Just when we're feeling poor, we're reminded of those who most definitely are not.
Like Stephen Hemsley, the CEO of UnitedHealth Group, who is still cashing in -- to the tune of $142 million the past two years -- on 10-year-old mega stock option grants. Or James Cracchiolo, the CEO of Ameriprise Financial, whose $18.8 million in total compensation included more than $9 million in "non-equity incentive pay." Cash, that is.
By now, you might think investors and the public would be desensitized to the size of these paychecks. Not so. Maybe it's the tough economy, but people seem angrier and more certain that every corporate executive is overpaid.
To that I say, no. Some CEOs deserve every penny they get. And directors, goaded by regulators, are finally responding to investor fury and reining in some of the abusive practices of the past.
Shareholders now having a say on pay practices could bring even bigger changes in the coming years. While the vote may be nonbinding, companies are discovering it carries more than symbolic clout.
Hewlett-Packard has been in damage control mode ever since shareholders said no to the pay package for its new CEO, Leo Apotheker, worth an estimated $85 million over the next five years. Johnson & Johnson, hoping to head off a similar result when its shareholders vote, defended CEO William Weldon's $28.7 million compensation in a letter to large institutional investors last week. In 2010, Weldon presided over 11 drug recalls, declines in both sales and stock prices, and the Food and Drug Administration's stepping in to supervise its consumer health care unit.
Also last week, General Electric, after "a number of constructive conversations with our shareowners," said it had changed the vesting formula on options awarded to its chief executive, Jeff Immelt.